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Chronic graft versus host disease (cGVHD) is a common long-term complication 
after allogeneic hematopoietic stem cell transplantation. The objective of our study 
was to compare the metabolic profiles for allotransplant recipients and thereby iden-
tify metabolic characteristics of patients with treatment-requiring cGVHD. The study 
included 51 consecutive patients (29 men and 22 women; median age: 44  years, 
range: 15–66 years) transplanted with peripheral blood stem cells derived from human 
leukocyte antigen-matched family donors. All serum samples investigated by global 
metabolomic profiling were collected approximately 1  year posttransplant (median 
358 days). Thirty-one of the 51 patients (61%) had cGVHD 1 year posttransplant. The 
affected organs were (number of patients) liver/bile duct (23), eyes (15), gastrointesti-
nal tract (14), skin (13), mouth (10), lungs (3), and urogenital tract (1). We compared 
the metabolic profile for patients with and without cGVHD, and a Random Forrest 
Classification Analysis then resulted in 75% accuracy in differentiating the two groups. 
The 30 top-ranked metabolites from this comparison included increased levels of 
bile acids, several metabolites from the cytokine-responsive kynurenine pathway for 
tryptophan degradation, pro-inflammatory lipid metabolites, phenylalanine and tyrosine 
metabolites derived from the gut microbial flora, and metabolites reflecting increased 
oxidative stress. However, nine of these 30 top-ranked metabolites were probably 
altered due to cyclosporine or steroid treatment, and we therefore did a hierarchical 
clustering analysis including all 51 patients but only based on the other 21 cGVHD- 
specific metabolites. This analysis identified three patient subsets: one cluster included 
mainly patients without cGVHD and had generally low metabolite levels; another cluster 
included mainly patients with cGVHD (most patients with at least three affected organs) 
and high metabolite levels, and the last intermediate group including cGVHD patients 
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with limited organ involvement. We conclude that allotransplant recipients with cGVHD 
have an altered metabolic profile caused both by the disease and its immunosuppres-
sive treatment.
Keywords: metabolomics, chronic graft versus host disease, stem cell transplantation, biochemical profiling, 
biomarkers
inTrODUcTiOn
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) 
is used in the treatment of severe bone marrow failure and 
aggressive hematological malignancies, including acute leuke-
mia (1, 2). The treatment approach depends on the ability of the 
engrafting immune system to remove residual leukemia cells via  
a graft-versus-leukemia effect (1). Allo-HSCT is then a poten-
tially curative treatment, although at the same time the treatment 
is associated with a relatively high risk of morbidity and mortality 
due to severe transplant-related complications (3). Chronic graft 
versus host disease (cGVHD) is then the most common cause 
of late non-relapse mortality (4–6). Guidelines for the diagnosis 
and treatment of this complication have recently been published 
(7). However, the complex immunopathology of cGVHD is still 
poorly understood (8), and preclinical models have weakness 
and limitations in the study of the disease (9). An increasing 
interest for biomarkers, to confirm diagnosis and prognosis 
in cGVHD, has evolved the last decade (10–13), although still 
no biomarkers are established in routine clinical practice (10, 
13). Among the risk factors for cGVHD are older patient age, 
previous acute GVHD (aGVHD), reduced intensity condition-
ing, female donor to male recipient, peripheral blood stem cell 
(PBSC) grafts and human leukocyte antigen (HLA) mismatched 
donors (14–19).
Graft versus host disease can be considered an exaggerated 
manifestation of normal inflammatory mechanisms in which 
donor lymphocytes encounter foreign antigens in a pro-
inflammatory milieu, and this inflammation involves several 
donor immunocompetent cell subsets (8, 9, 20–22). Metabolic 
regulation is important for immunoregulation, and we have pre-
viously demonstrated that pretransplant cytokine profiles as well 
as the pretransplant metabolic status of allotransplant recipients 
is associated with a risk of later aGVHD (23–25).
Our present study was initiated to compare patients with 
and without cGVHD 1 year posttransplant and thereby identify 
possible associations between the serum metabolic profile, the 
diagnosis and severity (i.e., organ involvement) of cGVHD 
requiring systemic immunosuppression, and the effects of this 
immunosuppressive (i.e., cyclosporine, steroids) on the metabolic 
profiles in cGVHD patients.
Abbreviations: aGVHD, acute graft versus host disease; allo-HSCT, allogeneic 
hematopoietic stem cell transplantation; cGVHD, chronic graft versus host disease; 
GC, gas chromatography; G-CSF, granulocyte-colony stimulating factor; GVL, 
graft-versus-leukemia; HLA, human leukocyte antigen; LC, liquid chromatogra-
phy; MS, mass spectrometry; PBSC, peripheral blood stem cell; PCA, principal 




The study was approved by the local Ethics Committee (Regional 
Ethics Committee III, University of Bergen, Norway; REK), and 
the samples were collected after obtaining written informed 
consent from the patients. The study included 51 consecutive 
allotransplant recipients (29 men and 22 women; median 
age: 44  years with range: 15–66  years) with HLA-matched 
family donors; these patients were transplanted during the 
period March 2006–December 2014. Ninety-five patients were 
transplanted in our institution during this period; 25 of them 
died from treatment-related causes, 6 patients relapsed, and 
13 were lost to follow-up. The decision to perform an allo-
HSCT was taken by the Norwegian Advisory Board for Stem 
Cell Transplantation and based on national guidelines. Thus, 
our study is population-based and includes an unselected and 
consecutive group of well-characterized patients with family 
donors. All samples were collected approximately 1 year post-
transplant (median 358  days). The patient characteristics are 
given in Table 1 and Figure 1. Patients were transplanted with 
granulocyte colony-stimulating factor mobilized PBSC. Most 
patients received GVHD prophylaxis with cyclosporine A plus 
methotrexate (n = 50), only one patient received cyclosporine 
A alone.
Detailed information about individual patients is given 
in Figure  1, including previous aGVHD, the presence of 
treatment-requiring cGVHD and when this was diagnosed, 
the type of cGVHD. All these patients were able to travel with 
public communication to come to the hospital for controls and 
blood sampling. All except two patients had active cGVHD 
requiring continued immunosuppression, but only four patients 
(patients 37, 38, 42, and 43) had platelet counts observed below 
100 × 109/L at the time of sampling (this was also true for the 
time of diagnosis).
Diagnosis of cgVhD
Chronic graft versus host disease was diagnosed according to 
generally accepted criteria based on careful clinical evaluation 
and additional biopsies for histological confirmation (7, 26).
Preparation of serum samples
All venous blood samples were collected into sterile plastic 
tubes (BD Vacutainer® SST™ Serum Separation Tubes; Becton-
Dickenson, Franklin Lakes, NJ, USA) and allowed to coagulate 
for 120  min at room temperature (18°C) before centrifugation 
(300  ×  g for 10  min) and serum collection. All samples were 
immediately frozen and stored at −70°C until analyzed.
TaBle 1 | Demographical, clinical, and laboratory data for the 51 patients included in the study.
Patient characteristics Observation +cgVhD −cgVhD
Demographic data and disease history
Gender (numbers) Male/female 29/22 19/12 10/10
Age (years, median and range) 44 (15–66) 44 (18–62) 43 (15–66)
Height (cm, median and range) 172 (149–193) 169 (158–190) 172 (149–193)
Weight (kg, median and range) 69 (42–133) 72 (47–133) 66 (42–98)
BMI (kg/m2, median and range) 23.4 (16.9–39.7) 23.7 (17.9–39.7) 22.2 (16.9–28.5)
Diagnosis (numbers) AML/MDS 31 22 9
ALL 13 8 5
CLL 2 0 2
MF 4 1 3
AA 1 0 1
Conditioning regimen (numbers) BU + CY 39 25 14
ATG + CY 1 0 1
TBI + CY 1 1 0
BEAM 1 1 0
TBI + ETO 1 0 1
FLU + BU 5 3 2
FLU + CY 2 0 2
FLU + BU + ATG 1 1 0
cGVHD organ involvement Liver (23 patients), eyes (15), gastrointestinal tract 
(14), skin (13), mouth (10), lungs (3) and urogenital 
tract (1).
Unless otherwise stated the values are presented as median with range given in parenthesis. Height and weight were registered at the start of conditioning therapy.
BMI, body mass index; AML, acute myelogenous leukemia; MDS, myelodysplastic syndrome; ALL, acute lymphoblastic leukemia; CLL, chronic lymphocytic leukemia; MF, 
myelofibrosis; AA, aplastic anemia; BU, busulfan; CY, cyclophosphamide; ATG, anti-thymoglobulin; TBI, total body irradiation; ETO, etoposide; FLU, fludarabine; cGVHD, chronic 
graft versus host disease.
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analysis of Metabolite serum levels
Metabolomic analysis was done in collaboration with 
Metabolon® (27). Briefly, samples were prepared using the auto-
mated MicroLab STAR® system (Hamilton Company, Bonaduz, 
Switzerland). A recovery standard was added prior to the first 
step in the extraction process for quality control. To remove 
protein, dissociate small molecules bound to protein or trapped 
in the precipitated protein matrix, and recover chemically 
diverse metabolites, proteins were precipitated with methanol 
under vigorous shaking for 2 min followed by centrifugation. 
The resulting extract was divided into four fractions: one for 
analysis by ultra-performance liquid chromatography-mass 
spectrometry (UPLC-MS)/MS with positive ion mode elec-
trospray ionization, the second for analysis by UPLC-MS/MS 
with negative ion mode electrospray ionization, the third for 
analysis by gas chromatography-mass spectrometry, and the 
last sample was reserved as a backup. Samples were placed 
briefly on a Zymark TurboVap® (McKinley Scientific, Sparta, 
NJ, USA) to remove the organic solvent. The samples for liquid 
chromatography (LC) were stored overnight under nitrogen 
before preparation for analysis. For GC, each sample was dried 
under vacuum overnight before preparation for analysis. A 
total of 755 metabolites of known identities (named biochemi-
cals) were analyzed in all samples (Table S1 in Supplementary 
Material).
Bioinformatical and statistical analyses
Bioinformatical analyses were performed using the J-Express 
(MolMine AS, Bergen, Norway) (28). For hierarchical clustering, 
all values were median variance standardized and log(2) trans-
formed. The complete linkage was used as the linkage method, 
and for distance measured the Pearson correlation was used. 
Statistical analyses were performed using the Statistical Package 
for the Social Sciences (SPSS) version 15.0 (SPSS Inc., Chicago, 
IL, USA). The Mann–Whitney U-test was used to identify 
biochemicals that differed significantly between groups. The 
Chi-Square test was used for analysis of categorized data. Unless 
otherwise stated p-values  <  0.05 were regarded as statistically 
significant.
resUlTs
allotransplant recipients are 
heterogeneous with regard to Their serum 
Metabolic Profile When Tested 1 Year 
Posttransplant
31 of the 51 patients included in the study (61%) had signs of 
cGVHD 1  year posttransplant; 29 of the 31 cGVHD patients 
required systemic immunosuppressive treatment either as pro-
longed or increased treatment with cyclosporine A (27 patients). 
Eleven of these 27 cyclosporine-treated patients (22% of the 
whole cohort) received combination treatment also including 
systemic steroid therapy, and two additional patients received 
mycophenolate mofetil monotherapy. The two last patients were 
diagnosed with cGVHD of the skin and received only topical 
steroid treatment. Thus, the large majority of the 31 cGVHD 
patients (29/31) received systemic treatment either as prolonged 
FigUre 1 | Continued
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FigUre 2 | Random forest analysis of the systemic metabolite profiles including all 51 patients; a comparison of patients with and without chronic graft versus 
host disease (cGVHD) and identification of the 30 top-ranked metabolites showing increased levels in patients with posttransplant cGVHD. Random forest 
analysis could distinguish between the metabolic signatures of patients with and without acute GVHD with a predictive accuracy of 75.0%. The figure presents 
the 30 top-ranked metabolites and their classification (indicated in the figure, lower right) based on their importance for the identification of the two patient 
subsets.
FigUre 1 | Clinical data of the 51 patients included in the study. The figure presents the clinical and demographical characteristics of the patients, including (from 
left to right) the presence of chronic graft versus host disease (cGVHD) and acute GVHD, the form of GVHD and the time when developing treatment-requiring 
cGVHD, organ involvement, ongoing immunosuppressive treatment at the time of sampling, and the clinical characteristics of the patients (hematological diagnosis, 
conditioning treatment, gender, female to male transplantation, and age). Abbreviations: AML, acute myelogenous leukemia; MDS, myelodysplastic syndrome; ALL, 
acute lymphoblastic leukemia; CLL, chronic lymphocytic leukemia; MF, myelofibrosis; AA, aplastic anemia; BU, busulfan; CY, cyclophosphamide; ATG, 
antithymoglobulin; TBI, total body irradiation; ETO, etoposide; FLU, fludarabine.
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or increased cyclosporine A therapy, or they received additional 
immunosuppression with oral prednisolone (daily doses 
2.5–40  mg) to maintain disease control. The most commonly 
affected organ was the liver/bile duct (23 patients; for additional 
details on organ involvement see Figure 1 and Table 1).
Seven of the 20 patients without signs of cGVHD received pro-
longed cGVHD prophylaxis at 1 year posttransplant due to either 
previous severe aGVHD and/or the presence of other risk factors 
for the development of cGVHD. Thus, a total of 34 patients (67%) 
received cyclosporine A 1 year posttransplant.
We first used principal component analysis (PCA) and hier-
archical clustering to analyze the overall metabolic profiles of the 
patients. However, these analyses could not distinguish between 
the 31 patients with and the 20 patients without cGVHD (data 
not shown); this is probably due to the metabolic heterogeneity 
for both patient subsets.
Patients with and without cgVhD Differ in 
Fatty acid and Bile acid Metabolism
In contrast to PCA and unsupervised hierarchical clustering, 
random forest analysis is an unbiased and supervised classi-
fication technique based on an ensemble of a large number of 
decision trees. In addition to producing a metric of predictive 
accuracy (Figure 2), this analysis also gives a list of the metabo-
lites ranked according to their importance for the classification 
scheme, i.e., their degree of difference between the two compared 
groups. Random forest analysis of serum metabolic profiles dif-
ferentiated patients with and without cGVHD with a predictive 
accuracy of 75%. Eighteen of the 30 top-ranked metabolites 
from this comparison reflected differences in lipid/fatty acid/
bile acid metabolism (Figure  2), most of them belonging to 
the annotations sphingolipids, plasmalogens/lysoplasmalogens, 
lysolipids, and phospholipids. We therefore compared the levels 
FigUre 3 | Hierarchical clustering analysis including all 51 patients and based only on 10 primary bile acid metabolites, identification of patient subsets with high 
frequency of chronic graft versus host disease (cGVHD) patients. We performed a hierarchical clustering analysis (Euclidian Correlation, complete linkage) based 
on the bile acid metabolites indicated to the right in the figure. The heat map and the corresponding dendrograms are shown in the figure. As indicated to the 
lower left in the figure red indicates high metabolite levels and green low levels. The clinical characteristics of each individual patient are presented in the upper part 
of the figure; for the lower horizontal bars the presence of a factor is indicated by red and the absence by green, whereas the color codes for the upper horizontal 
bars are explained in the figure. We identified two main clusters; the left included a major part of patients with cGVHD, whereas the right cluster included mainly 
patients without cGVHD. 28 of the 31 cGVHD patients clustered in the group with high bile acid metabolite levels, two patients clustered in the group with low 
levels, and the last cGVHD patient was an outlier. The frequency of cGVHD patients differed significantly between the two main clusters (Chi-square test, 
p < 0.0001).
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of all metabolites from these classes for patients with and with-
out cGVHD. These subclasses include a total of 122 metabolites 
(Table S1 Supplementary Material), and 46 of them were signifi-
cantly increased in patients with cGVHD.
Four of the 30 top-ranked metabolites (i.e., the secondary 
bile acid hyocholate and the primary bile acids glycochenode-
oxycholate sulfate, taurocholate, and glycocholate) reflect dif-
ferences in bile acid metabolism and were increased in patients 
with cGVHD (Figure  2). The subclass primary bile acids 
include 10 metabolites, and eight of them were significantly 
increased in patients with cGVHD. We therefore performed a 
hierarchical cluster analysis based on the serum levels of the 10 
primary bile acid metabolites (Figure 3). This analysis identi-
fied a minor subset of 14 patients with generally low levels of 
these metabolites and including 12 of the 20 patients without 
cGVHD; only two patients with cGVHD were included and 
both patients required systemic immunosuppression with only 
cyclosporine A alone. The remaining patients (a major subset 
of 36 patients together with one outlier) showed relatively high 
levels of most primary bile acid metabolites and thus included 
28 of the 31 patients with cGVHD, i.e., all patients requiring 
systemic steroids were included among these 37 patients. The 
difference in frequency of patients with cGVHD between 
these two groups was statistically significant (Chi-square test, 
p  <  0.0001). Finally, neither the cGVHD patients receiving 
cyclosporine alone, receiving additional systemic steroids nor 
having cGVHD with liver involvement clustered together in this 
analysis.
0 1 2 3 4 5 6 7 8 9
Fay Acid, Amino
Sterol
Primary Bile Acid Metabolism








Pyramidine Metabolism, Uracil containing
Secondary Bile Acid Metabolism
FigUre 4 | Metabolic pathway analysis based on the analysis of all 51 patients; a comparison of patients with and without chronic graft versus host disease 
(cGVHD). The figure presents the metabolic pathways with an enrichment score > 2 when comparing patients with and patients without cGVHD.
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a comparison of Patients with and 
without cgVhD by Metabolic Pathway 
analysis—increased levels of Metabolic 
Markers of inflammation, Protein 
Degradation and Oxidative stress in cgVhD
We next performed a metabolic pathway analysis to compare 
patients with and without cGVHD (Figure 4). The nine highest 
ranked metabolic classes included (1) amino fatty acid metabolism 
(a small class only including two metabolites in our analysis); (2) 
sphingolipid, plasmalogen, and lysoplasmalogen metabolites; (3) 
sterol and primary bile acid metabolites; (4) amino acid metabo-
lites (alanine and aspartate, glycine, serine, and threonine); and 
(5) amino sugar metabolism. Thus, this alternative analysis, 
which is based on the overall results and not only the highest 
ranked metabolites, shows that fatty acid/triglyceride/bile acid 
metabolism differs between patients with and without cGVHD 
not only when comparing the highest ranked metabolites but also 
when comparing the overall results.
The presence of cGVHD was associated with a metabolic 
signature consistent with ongoing inflammation and significantly 
increased levels of (1) the three lysolipid metabolites 1-linoleoyl-
GPC (18:2), 1-oleoyl-GPC (18:1), 1-palmitoleoyl-GPC (16:1), (2) 
the eicosanoid 12-HETE; and (3) the sphingolipid sphingosine 
(Figure  2) (29, 30). These signs of inflammation could still be 
detected despite the systemic immunosuppressive treatment for 
the large majority of the cGVHD patients. Furthermore, patients 
with cGVHD showed a significant increase in phennylacetat, 
3-(4-hydroxyphenyl) lactate, phenylalanine, and tyramine 
o-sulfate compared with patients without cGVHD; a possible 
explanation for these differences is altered gastrointestinal func-
tion (31), probably caused by gastrointestinal disturbances 
and altered microbial flora (Figure  5). Furthermore, increased 
levels of several markers for proteolysis and accelerated protein 
catabolism were also detected in the cGVHD patients (32), 
including N-acetylserine, N-acetylaspartate, N-acetylasparagine, 
N-acetylglutamate, and 1-methylhistidine (Figure 5).
Increased oxidative stress seems to be important in the 
pathophysiology of GVHD (33). The significantly increased 
levels in cGVHD patients of gamma-glutamyl amino acids 
(e.g., gamma-glutamylglutamate, gamma-glutamyltryptophan, 
gamma-glutamylphenylalanine, and gamma-glutamylthreonine) 
are consistent with an oxidative stress phenotype and increased 
activity of the gamma-glutamyl cycle that is important for recycling 
and regeneration of the antioxidant glutathione (34). Similarly, a 
significant increase in other oxidative stress markers, including 
alpha-tocopherol, cysteine sulfonic acid, and methionine sulfox-
ide (35), was also observed in cGVHD patients (Figure 5). Taken 
together, these observations suggest altered protein metabolism 
with disturbed redox homeostasis in cGVHD patients, and we 
therefore performed a hierarchical clustering analyses based on 
the 10 metabolites included in the term “oxidative stress” (Table 
S1 in Supplementary Material) (Figure  6). Two main clusters 
were then identified, and the frequency of cGVHD patients was 
significantly higher for the subset showing generally high levels 
of these metabolites (p = 0.0010, Chi-square test).
steroid Treatment of cgVhD is associated 
with increased levels of Phospholipids, 
lysolipids, Plasmalogen, 
Monoacylglycerol, and Diacylglycerol 
Metabolites
We first compared the metabolic profiles for the 11 patients 
receiving systemic steroid therapy versus all the other 40 patients. 
The 30 top-ranked metabolites are presented in Figure 7. 26 of 
the 30 top-ranked metabolites altered by systemic steroids were 
classified as lipid metabolites, and 20 of these lipid metabolites 
FigUre 5 | Altered phenylalanine/tyrosine metabolism (a) and altered proteolysis (B); a comparison of single metabolites including all patients with and without 
chronic graft versus host disease (cGVHD). [(a), upper part] The serum levels of the four metabolites phennylacetat, 3-(4-hydroxyphenyl) lactate, phenylalanine, and 
tyramine o-sulfate were significantly increased in cGVHD patients compared to patients without cGVHD. [(B), lower part] The serum levels of the proteolysis markers 
N-acetylserine, N-acetylaspartate, N-acetylasparagine, N-acetylglutamate, and 1-methylhistidine were significantly increased in cGVHD patients (marked with red) 
compared with patients without cGVHD (marked with green). All results are presented as the median, the 25%/75% percentiles and the variation range; results for 
cGVHD patients are presented as red boxes whereas patients without cGVHD are marked with green. The metabolites and the corresponding p-values  
(Mann–Whitney U-test) are shown at the top of each individual figure.
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belonged to the subclasses phospholipid (5 metabolites), lysolipid 
(7), plasmalogen (4), monoacylglycerol (3), and diacylglycerol 
(1). Thus, a major effect of systemic steroid treatment seems to be 
altered triglyceride/fatty acid metabolism.
We then did an alternative analysis and compared the meta-
bolic profiles for the nine cGVHD patients receiving systemic 
steroids together with cyclosporine versus the cGVHD patients 
only treated with cyclosporine, i.e., comparing two patient subset 
with similar cGVHD/cyclosporine status but differing with 
regard to steroid treatment (see Figure 1 for identification of the 
patients in these two subsets). The top-ranked metabolites from 
this comparison also included a large number of lipid metabolites 
(20 metabolites), and most of these metabolites were classified as 
phospholipid (three metabolites), lysolipid (8), plasmalogen (2), 
monoacylglycerol (2), and diacylglycerol (1). Thus, this compari-
son also suggests that a major effect of systemic steroid treatment 
of patients with cGVHD is an altered fatty acid/triglyceride 
metabolism.
Finally, the steroid-associated pattern presented in Figure 7 
was also reflected in our overall comparison of patients with 
and without cGVHD (Figure 2), although the phospholipid (2 
metabolites), lysolipid (1), plasmalogen (2), monoacylglycerol 
(none), and diacylglycerol (none) metabolites only constituted a 
minor subset (5 metabolites) among the 30 top-ranked metabo-
lites from this cGVHD comparison. These metabolites may 
reflect the systemic steroid treatment, but several of them are also 
increased during inflammation (29, 30), and alternatively reflect 
the more severe manifestation of cGVHD for patients requiring 
systemic steroids.
cyclosporine has Diverse effects on the 
systemic Metabolic Profile of 
allotransplant recipients and These 
effects are similar for Patients with and 
without cgVhD
We first compared the profile of all patients receiving cyclosporine 
(34 patients, including nine patients receiving combination treat-
ment with systemic steroids) versus all the other allotransplant 
recipients (17 patients); the 30 top-ranked metabolites are shown 
in Figure 8. It can be seen that cyclosporine treatment had diverse 
effects and was associated with altered levels of many different 
FigUre 6 | Altered serum levels of oxidative stress markers in patients with chronic graft versus host disease (cGVHD); a comparison of patients with and without 
cGVHD and including all 51 patients. [(a), upper part] We observed increased levels of seven metabolites classified as oxidative stress markers in cGVHD patients 
(red boxes) compared with patients without cGVHD (green boxes). All results are presented as the median, the 25%/75% percentiles and the variation range. The 
metabolites and the corresponding p-values (Mann–Whitney U-test) are shown at the top of each individual figure. [(B), lower part] We performed a hierarchical 
clustering analysis based on the 10 metabolites belonging to the group oxidative stress. The clinical characteristics of each individual patient are presented in the 
upper part of the figure; for the lower horizontal bars the presence of a factor is indicated by red and the absence by green, whereas the color codes for the upper 
horizontal bars are explained in the figure. Two main clusters could then be identified; one with generally high metabolite levels and another with generally low levels. 
The cluster characterized by generally high levels had a significantly higher frequency of patients with cGVHD (25 out of 32 cGVHD patients; p = 0.0010,  
Chi-square test).
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metabolites/metabolite subsets. Firstly, eight of these 30 metabo-
lites belonged to the subset amino acid metabolites, and none 
of them overlapped with the top-ranked metabolites for those 
patients receiving systemic steroids. However, 12 lipid metabo-
lites were also included among the top-ranked metabolites; 5 of 
these lipid metabolites belonged to the subclasses phospholipid/
lysolipid/plasmalogen and may therefore reflect alterations in the 
11 cGVHD patients receiving systemic steroid, although it should 
be emphasized that only 3 of the 12 lipid metabolites overlapped 
with the 30 top-ranked metabolites identified in the comparison 
of patients with and without steroid treatment (Figure 7).
We then compared the metabolic profiles for a subset of 
patients without cGVHD and receiving no immunosuppressive 
treatment with the subset of seven patients characterized by 
without cGVHD but still receiving prophylactic cyclosporine 
treatment 1 year posttransplant. These subsets can be identified 
from Figure  1; in this subset analysis we thus could compare 
two groups of patients with a similar cGVHD status (i.e., no 
cGVHD) but differing with regard to cyclosporine treatment. 
Even though the ranking of individual metabolites differed, one 
should emphasize that 27 of the 30 top-ranked metabolites from 
this comparison overlapped with the 30 top-ranked metabolites 
identified in the previous comparison of all patients receiving 
cyclosporine versus all the other patients (Figure 8).
Finally we compared (1) the 30 top-ranked metabolites previ-
ously identified by the comparison of all patients with versus all 
without cGVHD (Figure 2) versus the (2) 30 top-ranked metabo-
lites identified when we compared all patients with and without 
cyclosporine treatment (Figure  8). There was only a minor 
overlap including 5 heterogeneous metabolites between the 30 
top-ranked metabolites identified in each of these 2 analyses, and 
the 5 metabolites included N-acetylneuraminate (amino sugar 
metabolism), 2-aminooctanate (fatty acid, amino), 2-hydroxy-
octanoate (fatty acid, monohydroxy), lactosyl-N-nervonoyl-
sphingosine (d18:1/24:1) (sphingolipid), and sulfamethoxazole 
(drug). Thus, even though cyclosporine seems to have distinct 
5 10 15 20 25 30
2-acetamidophenol sulfate



































FigUre 7 | Random forest analysis based on the overall metabolomics profile for all 51 patients included in the study; a comparison of patients receiving and not 
receiving treatment with systemic steroids. Random forest analysis could distinguish between these two patient subsets with a predictive accuracy of 73.0%. The 
figure presents the 30 top-ranked metabolites and their classification (indicated in the figure, lower right) based on their importance for the identification of the two 
patient subsets.
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effects on the systemic metabolic profile in allotransplant recipi-
ents, the effects of cGVHD by itself seem to be stronger than the 
cyclosporine effects.
clustering analysis Based Only on 
Metabolites identified as cgVhD-
associated in random Forest analyses 
identifies Three Patient subsets with 
Different Frequencies of cgVhD
We compared the 30 top-ranked metabolites for the random for-
est analysis of all patients with and without cGVHD (Figure 2) 
and the 30 top-ranked metabolites from the analysis of all 
patients with and without cyclosporine treatment (Figure 8), and 
we then found 4 overlapping metabolites [lactosyl-N-nervonoyl-
sphingosine (d18:1/24:1), sulfamethoxazole, 2-hydroxyoc-
tanoate, and 2-aminooctanoate]. Similarly, when comparing the 
top-ranked metabolites for the cGVHD analysis (Figure 2) with 
the 30 top-ranked metabolites from the comparison of all patients 
with and without additional steroid treatment (Figure  7), we 
identified the five overlapping metabolites 1,2-dipalmitoyl-GPC 
(16:0/16:0), 1-(1-enyl-stearoyl)-2-linoleoyl-GPE (P-18:0/18:2), 
1-(1-enyl-stearoyl)-2-oleoyl-GPE (P-18:0/18:1), hyocholate, 
and 1-palmitoyl-2-oleoyl-GPC (16:0/18:1). Thus, the 30 top-
ranked metabolites from the comparison of all patients with 
and without cGVHD included 21 metabolites that only were 
associated with cGVHD but not with cyclosporine or steroid 
therapy.
We then did a clustering analysis of all 51 patients based on 
the 21 non-overlapping metabolites from the cGVHD random 
forest analysis (Figure  9). First, the middle cluster showed a 
low frequency of patients with cGVHD (3 out of 16), and this 
is significantly different from the other 35 patients (28/35; 
Chi-Square test, p  <  0.0001). Second, patients with cGVHD 
were mainly included in the two other clusters (11 out of 13 in 
the left and 17 out of 22 in the right cluster). The frequencies 
of patients with cGVHD did not differ significantly between 
these two clusters, but the frequency of patients with extensive 
cGVHD affecting at least three organs was significantly higher 
in the right cluster (10 out of 22 patients) than in the left cluster 
(2 out of 13 patients; Chi-Square test, p  =  0.027). Third, the 
frequencies of patients receiving cyclosporine treatment and 
additional steroid treatment did not differ between the right 
and left clusters, i.e., the two clusters including the majority 
of cGVHD patients. Thus, differences in immunosuppressive 
therapy cannot explain the localization of severely affected 
cGVHD patients mainly into one cluster. Finally, the two 
cGVHD patients without immunosuppressive therapy also 
clustered within the intermediate (left) cluster together with 
several other cGVHD patients.
Seven exceptional patients without cGVHD clustered together 
with the majority of cGVHD (Figure  9, left and right patient 








































FigUre 8 | Random forest analysis based on the overall metabolomics profile for all 51 patients included in the study, a comparison of patients receiving and not 
receiving treatment with cyclosporine. Random forest analysis could distinguish between these two patient subsets with a predictive accuracy of 60%. The figure 
presents the 30 top-ranked metabolites and their classification (indicated in the figure, lower right) based on their importance for the identification of the two patient 
subsets.
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clusters). Five of these exceptional patients (patients 2, 4, 24, 32, 
and 41) had a minor increase in liver enzymes at the time of blood 
sampling without other signs of cGVHD, but additional diagnos-
tic procedures were not indicated. Thus, they were classified as 
not having treatment-requiring GVHD in our study; the two last 
exceptional patients had no signs of cGVHD.
The three patient clusters were separated mainly due to the 
variation of 11 metabolites that clustered together in the lower 
metabolite cluster and included 5 amino acid metabolites 
(beta-citrylglutamate, alpha-ketoglutarate, glutamate, aspartate, 
and glycylvaline) and 4 bile acid metabolites (glycochenode-
oxycholate, glycocholate, glycohyocholate, and taurocholate) 
together with the 2 additional lipid metabolites sphingosine and 
1-arachidonoyl-GPA (20:4).
DiscUssiOn
Graft versus host disease is characterized by immune dysregula-
tion/deficiency, organ damage, and decreased survival (8, 9). 
Alloreactive T-cells have been implicated in its pathogenesis, but 
the precise role of specific T-cell subsets, autoantigens, alloanti-
gens, and B-cells as well as the contribution from immunoregula-
tory soluble mediators is not known (8, 9, 20–22). Thus, GVHD 
reflects an exaggerated response of inflammatory mechanisms 
that involve donor T cells as well as multiple innate and adap-
tive cells and various mediators. Moreover, the involvement of 
inflammatory and profibrotic cytokines, such as transforming 
growth factor beta or platelet-derived growth factor receptors, 
are also important for GVHD-targeted organ injury (8, 9, 36).
We decided to investigate the patients 1 year posttransplant. 
This time point was selected because the impact of pretransplant 
and early posttransplant factors on the metabolic profile was then 
expected to be low, the early hematological and immunological 
defects in reconstitution would be less important, a substantial 
number of patients would have developed cGVHD but the 
impact on the metabolic profiles from more severe organ failures 
was expected to be limited.
The present metabolomic profiling study was conducted to 
identify serum metabolic changes associated with cGVHD. To 
the best of our knowledge, this is the first study to investigate the 
metabolic profile of patients with cGVHD. Our results have to be 
interpreted with care because we investigated a relatively small 
group of patients, but the patients are relatively homogenous 
because all patients received grafts from matched family donors, 
most of them received the same GVHD prophylaxis and a limited 
number of conditioning treatments were used. Our study should 
also be regarded as population-based because our patient cohort 
represents all allotransplanted patients with a family donor from 
a defined geographic area and during a defined time period. 
Additional studies are therefore needed to investigate whether 
our results are representative also for other subsets of allotrans-
plant recipients (e.g., other donors).
We first compared all patients with and all patients without 
cGVHD, and this comparison suggests that cGVHD patients 
FigUre 9 | Hierarchical clustering analysis including all 51 patients and based on 21 selected metabolites. The analysis was based on the 30 top-ranked 
metabolites identified by the random forest analysis of the overall metabolic profile of all 51 patients and comparing patients with and without chronic graft versus 
host disease (cGVHD) (see Figure 2), but 9 of these 30 metabolites were excluded from this analysis because they overlapped with the 30 top-ranked metabolites 
identified by the comparison of patients with/without cyclosporine treatment (Figure 8) or with/without systemic steroid treatment (Figure 7). Based on the 21 
remaining metabolites we performed a hierarchical clustering analysis (Euclidian Correlation, complete linkage). The heat map and corresponding dendrograms are 
shown in the figure together with the clinical characteristics of individual patients (see horizontal bars in the upper part). The metabolites are listed to the right in the 
figure; red color means high metabolite levels and green color low levels as indicated to the lower left in the figure. The clinical characteristics of each individual 
patient are presented in the upper part of the figure; for the lower horizontal bars the presence of a factor is indicated by red and the absence by green, whereas the 
color codes for the upper horizontal bars are explained in the figure.
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have a unique metabolic signature (Figure  2). We examined 
the patients at a defined time point and the metabolic profile of 
our patients may therefore be influenced both by differences in 
immunosuppressive treatment, different duration of cGVHD 
and thereby also differences in cumulative effects by the ongoing 
pathological process. Despite this heterogeneity our random for-
est analysis could distinguish between patients with and without 
cGVHD with a predictive accuracy of 75%. The identification 
and validation of biomarkers in cGVHD remain very challeng-
ing (10–12), but our study suggests that metabolic markers may 
become useful in these patients.
As stated above, the altered metabolic profile in our cGVHD 
patients can be caused either by the disease itself or its treat-
ment, i.e., cyclosporine and/or systemic steroids. Several obser-
vations suggest that cyclosporine can affect systemic metabolic 
profiles. First, we analyzed all the 51 patients in our patient 
cohort and compared all patients with and all patients without 
cyclosporine treatment (Figure 8); the 30 top-ranked metabo-
lites from this comparison showed a minimal overlap (only four 
metabolites) with the 30 top-ranked metabolites from the com-
parison of all patients with versus all patients without cGVHD 
(Figure 2). Second, to further identify metabolic effects prob-
ably caused by cyclosporine treatment we compared our patient 
subset without cGVHD and still receiving cyclosporine with 
another subset  also being without cGVHD but not receiving 
cyclosporine, i.e., these two subsets had similar cGVHD status 
and differed only with regard to cyclosporine treatment. The 30 
top-ranked metabolites from these two comparisons of patients 
with and without cyclosporine treatment showed a large degree 
of overlap (27 metabolites). Thus, both these comparisons sug-
gest that cyclosporine has diverse effects on systemic metabolic 
profiles, and our present observations are consistent with 
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previous observations in kidney transplant recipients (37). 
We conclude that cyclosporine treatment can alter systemic 
metabolic profiles in allotransplant recipients, but our observed 
differences between patients with and without cGVHD cannot 
be explained by cyclosporine alone because the 30 top-ranked 
cGVHD-associated metabolites (Figure 2) included only four 
of the cyclosporine-associated metabolites (Figure 8).
We used the same strategy as for cyclosporine when we 
investigated the contribution from steroid treatment. First, we 
examined the whole patient cohort and compared all patients 
with and all patients without steroid treatment. When compar-
ing the results from this analysis (Figure 7) with the results from 
the with/without cGVHD comparison (Figure 2), we identified 
five overlapping metabolites, i.e., lipid metabolites associated 
both with cGVHD and systemic steroid therapy. Taken together 
these observations suggest that the increased levels of these 
overlapping metabolites in cGVHD patients are mainly due to 
the steroid treatment rather than the cGVHD. Our present results 
are consistent with previous studies of steroid-treated myasthenia 
gravis patients showing that steroids alter triglyceride/fatty acid 
metabolism (38). However, one cannot exclude the possibility 
that even these steroid-associated effects may be at least partly 
due to the more severe and thereby steroid-requiring cGVHD 
of these patients. This last possibility is actually supported by 
previous observations suggesting that increased levels of these 
lipid metabolites are also associated with inflammation (29, 30).
The altered levels of bile acid as well as tyrosine and phenyla-
lanine metabolites in cGVHD patients may reflect at least partly 
an altered microbiome composition. Previous studies have dem-
onstrated the complex and multidirectional interactions between 
inflammation, microbiota, and immune reconstitution in 
allotransplant recipients (39–43). Allo-HSCT can alter the intes-
tinal flora and this may then be more pronounced in individuals 
with cGVHD (39–41). The human gut microbiome is involved 
in vital biological functions, such as maintenance of immune 
homeostasis, modulation of intestinal function and metabolic 
regulation; disturbances of the intestinal microbiota can thereby 
be associated with development and progression of inflamma-
tion, including GVHD (44). The microbial intestinal flora is 
responsible for the generation of several metabolites derived from 
amino acids, bile acids, heme, and dietary sources; several of these 
metabolites are absorbed and can bind specific receptors on host 
cells. The metabolism of aromatic amino acids, phenylalanine, and 
tyrosine is partly due to enzymes encoded within the microbiome 
(44). Thus, a change in microbiome-derived metabolites might be 
due to a shift in the flora with translocation of pro-inflammatory 
metabolites or bacterial components into the systemic circulation 
and thereby further acceleration of GVHD through the release 
of pro-inflammatory cytokines such as tumor necrosis factor-
alpha and IL-1 (45, 46). Thus, our present observation supports 
the hypothesis that effects of altered microbiota on the systemic 
metabolic profile contribute to the biological and clinical impact 
of microbiota in allotransplant recipients (39–43).
Chronic graft versus host disease was associated with increased 
levels of primary bile acid metabolites. Bile acids are derived from 
cholesterol in the liver and released into the small intestine to 
facilitate dietary lipid absorption. Differences in serum bile acid 
levels may be caused by altered synthesis, release, or reabsorption. 
Bile acid malabsorption has previously been reported in GVHD 
(47), but an altered gut microbiome is an alternative explanation 
as discussed earlier. The increased levels of bile metabolites may 
then induce hepatic cell dysfunction and induction of pro-
inflammatory mediators (48).
Serum levels of multiple markers of inflammation and oxida-
tive stress were increased in our cGVHD patients (36), possibly 
reflecting an increased risk of inflammatory complications after 
allo-HSCT. Uremic toxicity, metabolic acidosis, and pro- 
inflammatory soluble mediators may activate protein degradation 
in cGVHD (25, 32, 49), and cGVHD may thereby be associated 
with altered metabolic and endocrine functions of several organs 
(8, 31, 36). An altered balance between protein synthesis and 
catabolism may then be the final result.
The altered lipid profiles in cGVHD may be due to differences 
in membrane lipid turnover. Immunocompetent cells switch 
from resting to activated state after stimulation, and this requires 
increased energy metabolism to fuel cell proliferation and acquire 
effector functions (50, 51). Disruption of lipid synthesis can 
reduce GVHD in murine models (52), indicating an important 
role of lipid metabolism in the pathogenesis of GVHD. Our find-
ings are in concordance with these observations.
Based on our overall results we did a final clustering analysis 
of our entire patient cohort to distinguish between cGVHD-
associated and treatment-associated metabolic effects in our 
patient cohort. Because we analyzed a relatively small number of 
patients, this analysis was based on the 30 top-ranked metabo-
lites from the initial with/without cGVHD analysis (Figure 2). 
We then excluded from these 30 metabolites the 9 overlapping 
metabolites identified by the comparisons of patients with/with-
out cyclosporine (Figure 8, four metabolites) and patients with/
without steroid (Figure 7, five metabolites). Thus, this analysis 
was based on 21 cGVHD-associated metabolites and included 
all patients in our cohort. We did not leave out from the analysis 
those metabolites that may be associated with an altered gastro-
intestinal microbiome because we regard the microbiome as a 
part of the overall clinical status of allotransplant recipients. The 
results from this last clustering analysis (Figure 9) showed that 
the patients were distributed in three main clusters; one cluster 
included mainly patients without cGVHD, a second cluster 
included mainly patients with cGVHD, but the disease involved 
only one or two organs for the large majority of these patients; 
and a third cluster including a majority of patients with cGVHD 
and many of them having involvement of at least three organs. 
This identification of three patient subsets could not be explained 
by pharmacological differences, and it was mainly caused by dif-
ferences in the systemic levels of five amino acid and six lipid 
metabolites (most of them being bile acids) that clustered together 
in Figure 9 (lower metabolite cluster). Finally, our two cGVHD 
patients not receiving immunosuppressive therapy clustered 
within the intermediate (left) cluster together with several other 
cGVHD patients; this observation further supports our view that 
this clustering analysis reflects differences in cGVHD-induced 
metabolic alterations.
To the best of our knowledge, this is the first study of systemic 
metabolic profiles in allotransplant recipients. We describe altered 
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metabolic profiles for patients with treatment-requiring cGVHD, 
and the overall profile includes effect due to both cGVHD itself 
and the immunosuppressive treatment. However, our study 
identified a subset of 11 metabolites that seem to reflect both the 
diagnosis and the severity of cGVHD.
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